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Abstract. Bone morphogenetic proteins (BMPs) belong to the
TGF-ß superfamily, which plays important roles in foetal and
postnatal development and also maintains the homeostasis of
various tissues and organs. Due to the critical role played by
BMPs in bone formation and bone turnover, the implication of
these molecules in bone metastasis has been intensively studied
over the past decade. BMPs have been implicated in the
development and progression of solid tumours, particularly the
disease-specific bone metastasis. In breast cancer, a tumour
type which most commonly metastasizes to bones, aberrations
of both BMP expression and their signalling have been
recently demonstrated. These aberrations have certain
correlations with the development and progression of the
disease. Recent in vitro studies have also demonstrated that
BMPs can regulate a range of biological functions of breast
cancer cells. Targeting BMPs or BMP signalling may provide
novel therapeutic approaches for breast cancer. In the
current review, we discuss the present knowledge on BMP
abnormalities and their implication in the development and
progression of breast cancer, particularly in the disease-specific
bone metastasis.
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1. Introduction
Bone morphogenetic proteins (BMPs) are members of the
TGF-ß superfamily, which participates in the development and
homeostasis of diverse tissues and organs through regulating
cellular differentiation, proliferation, apoptosis and motility.
BMPs exert their effects through a heteromeric receptor
complex, which comprises of two types of serine-threonine
kinase transmembrane receptors. The Type-I receptors include
Activin receptor-like kinase-1 (ALK-1), BMP receptor type IA
(BMPR-IA, also known as ALK-3), BMP receptor type IB
(BMPR-IB, or so-called ALK-6), ALK-4, ALK-5 and activin A
receptor type I (ActRI). The Type-II receptors include BMP
receptor type II (BMPR-II), activin A receptor type IIA
(ActRIIA) and activin A receptor type IIB (ActRIIB). Upon
binding to BMP ligands, the Type-II receptors then phos-
phorylate the glycine-serine (GS) domain of Type-I receptors.
This leads to the recruitment of the pathway-restricted Smads
(R-Smads, Smads1, 5 and 8) to the complex. The intracellular
signaling complex of R-Smads is then translocated into the
nucleus after binding with Smad-4, which leads to the
regulation of BMP responsive genes. This pathway is known
as the Smad-dependent pathway, in which Smad-6 and -7 act
as inhibitory regulators to the signalling. The other pathway
is known as the Smad-independent pathway, in which the
mitogen-activated protein kinase (MAPK) pathway and the
RAS pathway, may be involved (1).
BMPs are key factors in regulating bone formation and
bone turnover and have been recently shown to play a pivotal
role in tumour development, progression and bone metastasis
(1). Breast cancer is the most common cancer in females in the
UK and the USA and is the second leading cause of death from
cancer. Its leading metastatic site is bone. The major bone
lesion in breast cancer is osteolytic, which leads to bone pain,
fractures, spine cord compression and hypercalcaemia. These
morbidities severely impact the quality of life of the patients.
The attention to BMPs and their role in breast cancer has
increased as substantial progress has been made in this area.
The present review summarises the current knowledge on the
roles played by BMPs in breast cancer and their therapeutic
potential.
2. BMPs and tumour biology of breast cancer cells
The roles of BMPs in the biology of breast cancer cells have
been intensively investigated over the past decade. It is now
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known that BMPs are extensively involved in the regulation
of cellular functions of breast cancer cells, ranging from cell
growth and death, cell migration, invasion and epithelial-
mesenchymal transition (EMT).
Cell cycle and proliferation. BMPs are able to regulate the
growth of breast cancer cells. However, the nature of cell
response is influenced by the individual BMP, namely, with
some BMPs having an inhibitory effect on proliferation of
breast cancer cells, while others show a reverse effect (Fig. 1A).
For example, BMP-2 and BMP-6 inhibit the proliferation of
breast cancer cells (2,3). On the other hand, some BMPs may
indirectly promote the proliferation of breast cancer cells, such
as BMP-4 which has a synergetic effect on the proliferation
of breast cancer cells induced by fibroblast growth factor
(FGF), epidermal growth factor (EGF) and hepatocyte growth
factor (HGF) (4). This contrasting effect on proliferation of
breast cancer cells was clearly demonstrated in a recently
published study, where BMP-7 promoted proliferation of
MDA-MB-231 and BT-474 cells, but showed an inhibitory
effect on the other breast cancer cell lines tested (5).
BMPs can also co-regulate the growth of breast cancer
cells induced by non-cytokine agents. For example, BMP-2
inhibits estrodiol-induced proliferation of breast cancer cells,
via up-regulation of cyclin kinase inhibitor, p21 which in turn
inhibits the estradiol-induced cyclin D1-associated kinase
activity (6). The up-regulation of p21 by BMP-2 can also
prevent EGF-induced proliferation of breast cancer cells
(MDA-MB-231) (7). BMP-2 has a direct anti-proliferative
effect on tumour cells at a very high concentration (1 μg/ml)
in vitro (8). It is interesting to note that the regulation of p21
expression by BMP-2 was mediated by Type-I receptors,
Smad-1 and Smad-4. In MDA-MB-468, which only
expresses Smad-1, BMP-2 fails to induce p21 and inhibits
cellular proliferation (9). BMP-6 inhibits proliferation and
induces cell cycle arrest at G0/G1 stage in oestrogen-
insensitive breast cancer cells (MDA-MB-231) (2).
To the same BMP protein, different breast cancer cell lines
may have a different response. For example, MDA-MB-231,
an ER-negative tumour cell line, responds to recombinant
human BMP-2 with a greatly reduced proliferation, in
comparison to the ER-positive MCF-7 cells (3). This
suggests that the oestrogen receptor (ER) status has a bearing
on the cell response to BMPs. This link is further strengthened
by a study which revealed that BMP-6 and BMP-7 could
inhibit oestrogen-induced mitosis of ER-positive breast cancer
cells (10).
Apart from the ER status affecting the function of BMPs in
breast cancer cells, the BMP receptors must be critical for
this diversity due to their essential role in mediating BMP
signalling. Recent studies have highlighted certain BMP
receptors mediating contrasting effects in breast cancer cells.
Overexpression of a domain-negative BMPR-II in breast cancer
cells is able to interfere with the phosphorylation of Smad-1
by BMPR-II, leading to an arrest of the cancer cells at the G1
phase of the cell cycle. This suggests that coupling between
BMPs and BMPR-II has a significant role in controlling the
proliferation and survival of breast cancer cells (11). A domain-
negative Type II TGF-ß receptor (dnTßRII) could eliminate
the anti-proliferative effect of BMP-2 in breast cancer cells
by preventing the phosphorylation of Smad-1 (12). One of
the Type I receptors, BMPR-IA (ALK-3) has been recently
shown to be involved in the activated Smad pathway which
contributes to development and progression of breast cancer
at primary and secondary sites (13). While BMPR-IA and
BMPR-II play positive roles for BMP induced proliferation
and aggressiveness in breast cancer cells, another Type I
receptor, BMPR-IB has been indicated as a negative regulator
(14).
Taken together, BMPs induce diverse effects in breast
cancer cells due to the phenotypic profile of BMPs receptors,
intracellular signalling molecules and regulatory factors.
Apoptosis. In addition to the pivotal role in the control of cell
proliferation and growth, BMPs also play a profound role in
regulating apoptosis of breast cancer cells (Fig. 1A). Most
interestingly, BMPs can induce a biphasic effect on apoptosis
in breast cancer cells depending on the type of BMPs, cell type
and experimental circumstances. For example, under routine
culture conditions, BMP-2 showed a pro-apoptotic effect in
some breast cancer cells (MCF-7), in which the expression
and function of apoptosis related genes, particularly protein
kinase R (PKR) and subsequent activation of its substrate
eIF2· are regulated by the BMP (15). Under different experi-
mental conditions, BMPs may play a contrasting role in
regulation of apoptosis. For example, without supplement of
serum, BMP-2 increases the resistance of breast cancer cells
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Figure 1. Influences on biological functions of breast cancer cells by BMPs.
(A) BMPs regulate the proliferation and apoptosis of breast cancer cells.
(B) The effect on cell motility and EMT of breast cancer cells by BMPs.
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(MCF-7) to hypoxia-induced apoptosis, via the activation of
both the MAPK pathway and ID-1 and suppression of
caspase-3 (16,17). The other example is BMP-6, which can
inhibit the proliferation of breast cancer cells (MDA-MB-231).
Under deprivation of serum, BMP-6 turns to protect these
cancer cells from stress-induced apoptosis through up-
regulation of survivin via the Smad-dependent pathway and
activation of p38 via the Smad-independent pathway and both
contributed to the anti-apoptotic effect of BMP-6 (2).
Motility and invasiveness of tumour cells. Motility and
invasiveness are essential capacities for cancer cells to
disseminate and spread. The possible role BMPs play in
regulation of cancer cell motility and invasiveness remains a
topic of investigation (Fig. 1B). BMP-2 has shown a pre-
dominant effect in promoting the motility and invasiveness
of breast cancer cells. For instance, BMP-2 promotes the
aggressiveness of breast cancer cell (MCF-7) growth, in vitro
and in vivo, in an oestrogen-independent manner (18). BMP-7
is also capable of promoting cell migration and invasion (5).
These interesting observations certainly deserve additional
research into the scope and the underlying mechanism(s) by
which cell migration is affected by BMPs.
BMP-2 may contribute to the invasiveness of tumour cells
via the induction of tenascin-W in the tumour surrounding
stroma. Tenascin-W belongs to a family of extracellular matrix
glycoproteins. It has been shown to be highly expressed in the
stroma around breast carcinoma lesions and has been linked
to the aggressiveness of tumour cells via its interaction with
the ·8 integrin. HC11 cells derived from normal mammary
epithelium do not express ·8 integrin and fail to cross
tenascin-W-coated filters. However, 4T1 mammary carcinoma
cells do express ·8 integrin and their migration is stimulated
by tenascin-W. BMP-2 can induce the expression of tenasin-W
through the p38 MAPK and JNK pathway. This is in clear
contrast to TGF-ß1, which is a potent inducer of tenascin-C
(19). Finally, up-regulation of ID-1 by BMP-2 may be another
contributing factor in BMP-2 related aggressiveness of breast
cancer cells (20).
On the other hand, some other BMPs may have an
inhibitory effect on the aggressiveness of breast cancer cells.
For example, forced expression of GDF-9a in breast cancer
cells could reduce their invasiveness in vitro (21). BMP-2 has
been demonstrated to inhibit collagenase-3 in some bone cell
types. Collagenase-3 (MMP-13) is expressed by hypertrophic
chondrocytes, periosteal cells and osteoblasts during human
fetal bone development. The expression of MMP-13 was
enhanced by TGF-ß, but was inhibited by BMP-2 (22).
However, whether this is implicated in the invasiveness of
breast cancer cells is still unknown.
Epithelial-mesenchymal transdifferentiation/transformation
(EMT). EMT regulated by BMPs has been implicated in foetal
and postnatal development of different organs and tissues.
EMT is also an important event during the development and
progression of cancer. EMT not only causes a disruption of
epithelial homeostasis which may lead to carcinogenesis, it
can also transform the indolent tumour cells into a more
aggressive colony, leading to metastasis. BMP-4 can subvert
the ability of mammary epithelial cells to form polarized
lumen-containing structures and also endows them with
invasive properties (23). This supports the involvement of
this BMP cytokine in the progression of breast cancer. In the
bone metastasis-derived PC-3 prostate cancer cell line, BMP-7
has been shown to induce epithelial-mesenchymal trans-
differentiation with classical changes in morphology and
promote both motility and invasiveness in prostate cancer
cells (24). However, in mammary epithelial cells (NMuMG),
BMP-7 was not able to induce EMT whereas TGF-ß1 could
(25). In contrast, some BMPs are able to reverse EMT and
reduce the aggressive properties of tumour cells. For example,
BMP-6 restores E-cadherin-mediated cell-to-cell adhesion
and prevents breast cancer metastasis through the down-
regulation of ‰EF1. Higher level of ‰EF1 expression is
associated with a more invasive phenotype of breast cancer
cells (26). Another example is BMP-7, which is able to increase
cytokeratin expression and decrease vimentin in breast
cancer cells in vitro and in vivo, leading to an epithelial-like
phenotype (27) (Fig. 1B).
BMPs and tumour related angiogenesis. Angiogenesis is an
important event during the development and progression of
both primary and secondary tumours. Current knowledge
regarding the role of BMPs and angiogenesis is mainly from
studies in prostate cancer and bone formation. It has been
demonstrated that BMPs, including BMP-2, -4, -6, -7 and
GDF5, are capable of inducing angiogenesis. This may be one
of the ways by which these BMPs contribute to the process
of bone formation (28,29). Experimental evidence suggests
that BMPs promote angiogenesis indirectly through up-
regulation of the expression of VEGF in both prostate cancer
cells and osteoblasts (30,31). The early stage of bone induction
by rhBMP-2 can be blocked by the anti-angiogenic agent,
TNP-470 (28). This evidence suggests that the control of
angiogenesis by BMPs may be, to some extent, coupled with
osteoblastic activity.
Presently, the understanding of the role of BMPs in
angiogenesis in breast cancer is poor. There is very limited
literature in this aspect, one study has reported that BMP-2
promotes tumour-related angiogenesis through stimulating p38
MAPK pathway and ID-1 (32). This is obviously a fertile area
for explorers.
3. Crosstalk between BMPs and estrogen signalling
The involvement of oestrogen in the development and
progression of breast cancer is well established. Prolonged
exposure to oestrogen in circumstances such as early menarche,
late menopause and nulliparity has been considered as high
risk to developing breast carcinoma. The effect of oestrogen is
largely mediated through two oestrogen receptors, ER-·
(ESR1) and ER-ß (ESR2). ER status is correlated with
prognosis of patients with breast cancer and is thus a key
indicator for selecting endocrine therapies. A possible
relationship between BMP/BMP receptor signalling events and
ER is an interesting topic. Some of the recent studies have
shown some positive correlations.
First, it seems that oestrogen is able to regulate the
expression of BMP and BMP receptors. Oestrogen can repress
the expression of some BMP receptors, such as BMPR-IA,
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BMPR-IB, ACVR2A, and ACVR2B, but has no effect on the
expression of ACVR1 and BMPR-II (10). In line with this
observation, the expression of some BMPs and BMP receptors
in breast cancer tissues has been shown to correlate with ER
status. The expression of BMP-7 has been found to highly
correlate with the expressing level of both estrogen receptor
(ER) and progesterone receptor (33). Using enzyme restriction
PCR (MSRE-PCR), as well as bisulfate sequencing (BSG),
methylation of the human BMP-6 gene promoter was detected
in MDA-MB-231; while in MCF-7 and T47D, the BMP-6
gene promoter remained demethylated. In 33 breast tumour
specimens, promoter methylation of BMP-6 was detected by
methylation-specific PCR. Hypermethylation of BMP-6 was
observed in ER-negative cases [16 of 16 cases (100%)], while
obviously lower methylation frequency were observed in ER-
positive cases [3 of 17 cases (18%)], indicating that BMP-6
promoter methylation status correlates with ER status in breast
cancer (34). Different roles played by ER-· and ER-ß in the
regulation of BMPs have been otherwise revealed in osteoblast-
like cells. Anti-oestrogen reagent raloxifene could increase the
activity of the BMP-4 promoter in U-2 OS osteoblast-like
cells. ER-·, but not ER-ß‚ is thought to be indispensable for
this effect on the BMP-4 promoter. However, ER-ß may
synergetically enhance this activation of the BMP-4 promoter
by raloxifene (35). The role played by ER-ß in the regulation
of BMPs and BMP signalling by oestrogen in breast cancer
cells remains unclear.
On the other hand, oestrogen and BMPs can influence each
other's function through interaction between their receptor and
downstream signalling. Oestrogen can interfere with the
biological function of BMP-2 by inhibiting the activation of
Smad, as a result of biochemical interaction between Smad
and oestrogen receptor (ER) (36). BMP signalling molecules
also have some influence on the signalling events of oestrogen
via the interaction with ERs. Smad-4 is indispensible for the
Smad-dependent signalling by BMPs and other TGF-ß family
members. It has also been shown that an association between
Smad-4 and ER-· prevents the transcriptional regulation
mediated by ER-· (37) (Fig. 2). However, the interaction
between the oestrogen signalling pathway and the BMP
pathway and their implication in breast cancer still needs more
exploration.
Several other factors and pathways have been indicated in
the regulation of BMP expression and function. This includes
the interrelationship between BMPs and other members of the
TGF-ß (13), EGF (33), HGF and HGF receptors (38-40).
BMPs may also have implications with other factors such as
Tumour-associated trypsin inhibitor (TAT1) (41), ID-1 (17)
and PTEN (42).
4. The expression pattern of BMPs and BMP receptors 
in mammary gland and primary mammary tumours
The aforementioned roles of BMPs and BMP receptors in
breast cancer and in bone metastasis undoubtedly sparked
substantial interest in examining the expression pattern of
these molecules in clinical breast cancer. A few BMPs have
been since investigated, however often with inconsistent
results. BMP-6 mRNA was detectable in breast carcinoma
tissues, its level was reduced in breast carcinoma (18/44)
compared with tumour-free resection margins. However,
higher levels of BMP-6 mRNA were also found in 8 of the
44 patient samples in comparison with non-tumour margins
(43). BMP-2 transcript was decreased in breast primary
tumour, in contrast to that of activin-ßA and osteopontin
(OPN), which were elevated in these primary tumours (44).
Decreased BMP-7 expression in primary tumours was
associated with bone metastasis (27). Decreased expression
of GDF-9a and BMP-12 was seen in breast cancer compared
to matched background tissue and lower expression levels were
associated with poor clinical outcome (21,45). A more recent
study from the host lab examined the expression of BMP-2 to
BMP-7 in a breast cancer cohort using immunohistochemical
staining and quantitative PCR. The results showed that BMP-2
and BMP-7 were decreased in breast cancer and correlated
with poor prognosis (46).
In contrast to these findings, elevated expression of BMPs
has been demonstrated in other studies. For example, BMP-7
was only seen in nuclei of breast cancer cells, but was not
detectable in normal breast tissue using immunohistochemical
staining (47). BMP-2 and BMP-4 were highly expressed in
invasive breast cancer compared to the adjacent normal
mammary tissue (16). BMP-4 and BMP-7 were elevated in
breast cancer compared to normal breast tissue (48,49). Up-
regulated BMP-7 expression in primary tumours may correlate
with the disease-specific bone metastases of breast cancer
(50). BMP-5 was highly expressed in breast cancer and the
increasing expression correlated with poor prognosis (46).
Meanwhile, investigations into the expression patterns of
BMP receptors and intracellular signalling molecules have
also been conducted, but to a rather limited extent. Elevated
expression of BMPR-IB was associated with high tumour
grade, high tumour proliferation, cytogenetic instability and a
poor prognosis in oestrogen receptor-positive carcinomas (51).
This suggests that the expression of this type I receptor may
associate with the ER status and is regulated by estrogen.
The results from the host lab showed a decreased level of
BMPR-1B in breast cancer, which was associated with poor
prognosis (52).
Activation of the Smad pathway of BMPs (Smad1/5/8)
and TGF-ß (Smad2) was revealed in nuclei of breast cancer
cells in both primary tumours and bone metastases and similar
involvements were also seen in an in vivo model. TGF-ß3
and BMP-2 could promote motility and invasiveness of breast
cancer cells (MDA-231-D) in vitro. Moreover, expression of
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Figure 2. Crosstalk between oestrogen and BMP signalling in breast cancer
cells.
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domain-negative receptors for TGF-ß and/or BMPs in the
MDA-231-D cells inhibited invasiveness in vitro and bone
metastasis in the xenograft model. These results suggest that
BMPs as well as TGF-ß promote invasion and bone metastasis
of breast cancer (13).
In contrast to investigation into clinical breast cancer,
studies on the expression of BMPs in breast cancer cell lines
appear to be more consistent. Semi-quantitative PCR indicated
that BMP-2 and BMP-3 but not BMP-4 and BMP-7, were
present in MDA-MB-231 and MCF-7 cells. BMPR-1A,
BMPR-1B and BMPR-2 were all detectable in both breast
cancer cells at mRNA level. Both transcripts and protein of
BMP-2 in MDA-MB-231 cells were decreased in exposure to
radiation, whereas the level of BMP-2 in MCF-7 cells was
not changed after radiation (3). This provided information for
in vitro studies of BMPs in breast cancer.
Although the expression of specific BMPs, such as BMP-2,
-4, -6 and -7 in breast cancer is still controversial, the aberrant
expression of these BMPs and BMP receptors has been
indicated in the development and progression of breast cancer
(Table I). The aberrations in the BMP phenotype and signalling
in breast cancer, may due to the ER status and self-adjustment
by tumour cells themselves according to the needs for
development and progression at different stages.
5. BMPs and bone metastasis from breast cancer
Both clinical and experimental studies suggest profound roles
for BMPs in bone metastasis of breast cancer. Decreased
expression of BMP-7 has been indicated in primary tumours
in association with bone metastases. BMP-7 is able to inhibit
the growth of breast cancer tumours at primary sites and in
bone in vivo (27). Orthotropic implant of tumours with silk
scaffolds which were coupled with bone morphogenetic
protein-2 (BMP-2) and seeded with bone marrow stromal cells
(BMSC), contributed to metastatic spread of breast cancer
cells (53). These studies suggest that BMPs are involved in
the bone metastasis of breast cancer. On the other hand, lack
of BMP antagonists in breast cancer may contribute to the
osteoblastic lesions of breast cancer. Conditioned medium
(CM) from breast cancer cells (HT-39) could result in an
up-regulation of bone sialoprotein mRNA expression in
osteoprogenitor cells (MC3T3-E1 cells) and a promotion of
their osteoblastic behaviour. This effect could be blocked by
addition of Noggin, a BMP antagonist (54). A more recent
study also demonstrated that lack of the noggin expression in
both breast and prostate cancer cells was associated with
osteoblastic activities in the bone metastases. Forced expression
of Noggin in an osteo-inductive prostate cancer cell line
(C4-2B) reduced in vivo osteoblastic responses induced by its
intravenous xenografts, but had little or no influence on bone
resorption and tumour growth (55). Unlike Noggin, another
BMP antagonist, Gremlin, has been demonstrated to be
overexpressed in some human cancers, including breast
cancer (56). However, the roles that Gremlin and other
BMP antagonists play in coordinating the osteoblastic and
osteolytic activities in bone metastatic lesions are far from
clear.
CM from breast cancer cells (MCF-7) or prostate cancer
cells (LNCaP) could up-regulate osteopontin (OPN) in
osteoblasts through the protein kinase C (PKC) pathway and
mitogen-activated protein kinase (MAPK) pathway. This
resulted in inhibition of proliferation and differentiation in
osteoblastic cells (57). Another study showed CM from breast
cancer (MCF-7) cell-induced apoptosis in preosteoblastic cells
(FHSO-6) (58).
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Table I. BMP and BMP signalling in breast cancer.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Effect on 
Expression in breast cancer Functions in breast cancer cells in vivo tumour
––––––––––––––––––––––––––––– –––––––––––––––––––––––––––––––– –––––––––––––––
Primary tumour Bone metastasis Proliferation Apoptosis Motility Primary Bone
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BMP-2 ↓/↑ ↓/- ↓/↑ ↑ ↑ ↑
BMP-3 ↓
BMP-4 ↑ ↑
BMP-5 ↑
BMP-6 ↓/↑ ↓ ↓
BMP-7 ↓/↑ ↓ ↓/↑ ↑ ↓ ↓
GDF-9a ↓ ↓ ↓
BMP-15 ↓
BMPR-IA ↑ ↑
BMPR-IB ↓/↑ ↓
BMPR-II ↑
p-Smad-2, -3 ↑
p-Smad m,-1, -5, -8 ↑
Noggin - ↓
Gremlin ↑
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BMP and BMP signalling in breast cancer. ↓, stands for decrease or inhibit; ↑, stands for increase or promote; –, stands for no effect; blank
represents unknown.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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6. Perspectives and therapeutic potential
Aberrant expression of BMPs and BMP signalling has been
implicated in breast cancer and disease-specific bone
metastasis. The expression of some BMPs in primary tumours
may have predicting potential, such as that expression of
BMP-7 may be associated with bone metastasis and decreasing
levels of Noggin may indicate bone metastasis and more
osteoblastic activites in bone lesions.
The more recent studies have demonstrated activation of
BMP signalling in both breast primary tumours and bone
metastases, which contribute to aggressiveness of tumour cells,
and development of bone lesions. Lack of Noggin in both
breast and prostate cancer cells correlates with their active
osteoblastic feature. In the in vivo bone tumour model, Noggin,
an antagonist of BMPs, has been shown to prevent bone
metastasis by inhibiting both osteoblastic and osteolytic
processes. These findings collectively indicate a promising
therapeutic value for BMPs and their antagonists in the
management of bone metastases.
BMPs and their signalling play a profound role in the
development, progression and metastasis of breast cancer.
Further investigation will elucidate the mechanisms underlying
the involvement of BMPs in breast cancer. It will expand
current understanding for the pathogenesis of breast cancer and
may provide clues for developing novel therapies in managing
advanced diseases.
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